Latest Headlines

31. Siegfried DINAMIQS Receives Swissmedic License For Viral Vector Manufacturing 9/24/2026
32. Siegfried Obtains Antitrust Clearance For Acquisition Of Three Drug Substances Sites In The US And Australia 9/24/2026
33. Siegfried Shareholders Approve All Proposals At Annual General Meeting 2026 9/24/2026
34. Siegfried Delivers Strong Profitability And Continued Growth 9/24/2026
35. METTLER TOLEDO Showcases New Product Inspection Technologies At Pack Expo 9/23/2026
36. Emulate Enters Final Stage Of FDA ISTAND Program For Human Liver-Chip With Submission Of Qualification Package Covering Both Zoë® And AVA™ Organ-Chip Platforms 9/18/2026

    Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, today announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) full qualification package (FQP) for its Human Liver-Chip, advancing the company’s efforts to establish Organ-on-a-Chip technology as a qualified Drug Development Tool (DDT) for drug-induced liver injury (DILI) assessment.

37. Advancing Pharmaceutical Manufacturing With Esco Lifesciences At ISPE 2026 9/17/2026
38. Upperton Granted MHRA Licence For Annex 1 Aligned Sterile Manufacturing Facility 9/17/2026

    Upperton, a UK-based contract development and manufacturing organisation (CDMO), today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a variation to its existing Manufacturing and Importation Authorisation for Investigational Medicinal Products (MIA(IMP)) licence, extending its scope to include the company’s new Annex 1-aligned sterile manufacturing facility at Trent Gateway, Nottingham.

39. Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation In Clinical Study 9/17/2026

    Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorithm selected modified-release formulation compositions and doses during the trial. The algorithm reached the study's preset pharmacokinetic target within three dosing periods, meeting the program's interim objectives.

40. Hovione Opens New Facility At New Jersey Campus, Doubling U.S. Spray Drying Capacity 9/16/2026

    Hovione, a globally-integrated pharmaceutical Contract Development and Manufacturing Organization (CDMO), has opened 89 Twin Rivers, a new 31,000-square-foot facility at its East Windsor, N.J. campus that doubles the company's U.S. spray drying capacity and further reinforces Hovione´s global leadership in this technology platform.